

2025 Financial Statements

These figures are extracted from the complete annual report 2025 of Stichting International Kidney Cancer Coalition in Utrecht, Netherlands as determined by the Board on 24th March 2026.

This annual report has been provided with an unqualified auditor's report, by Accent on Audit BV.

Bart van Goudoever

Bart van Goudoever
Secretary/Treasurer

Stichting International Kidney Cancer Coalition

Ouder-Amstel, the Netherlands

1. FINANCIAL STATEMENTS

Stichting International Kidney Cancer Coalition
Computerweg 22
3542 DR Utrecht
The Netherlands

Chamber of Commerce: 62070665

Stichting International Kidney Cancer Coalition

1.1. Balance sheet as of 31 December 2025

(After appropriations of results)

ASSETS	31 December 2025		31 December 2024	
	€	€	€	€
Fixed Assets				
Tangible fixed assets				
Hardware & software	694		--	
Total fixed assets		694		--
Current Assets				
<i>Receivables</i>				
Other prepayments and accrued income	47,778		67,725	
		47,778		67,725
<i>Securities</i>		710,978		682,367
<i>Cash at bank and in hand</i>		63,341		450,259
Total current assets		822,097		1,200,351
TOTAL ASSETS		822,791		1,200,351

Stichting International Kidney Cancer Coalition

1.1. Balance sheet as of 31 December 2025

(After appropriations of results)

LIABILITIES	31 December 2025		31 December 2024	
	€	€	€	€
Foundation's capital				
Restricted reserves	148,935		453,711	
Unrestricted reserves	<u>579,897</u>		<u>658,526</u>	
		728,832		1,112,237
Current liabilities				
Accounts payable	47,100		60,321	
Accruals and other payables	<u>46,859</u>		<u>27,793</u>	
		93,959		88,114
TOTAL LIABILITIES		<u>822,791</u>		<u>1,200,351</u>

Stichting International Kidney Cancer Coalition

1.2. Statement of income and expenditure 2025

	2025	2024
	€	€
Income	381,797	620,175
Expenditure	772,616	882,049
Operating result	(390,819)	(261,874)
Financial income & (expenses)	7,414	64,944
Result for the year	(383,405)	(196,930)
The amendment of reserves is divided as follows		
Restricted reserves Global Kidney Cancer Summit	(134,111)	(142,375)
Restricted reserves World Kidney Cancer Day	(53,105)	(126,689)
Restricted reserves DISCERN	(28,646)	(1,246)
Restricted reserves Shared Decision Making	(25,562)	(40,117)
Restricted reserves CARE1	(7,375)	(3,824)
Restricted reserves Dashboard Project	(1,457)	(1,694)
Restricted reserves Global Patient Survey	--	(107,605)
Restricted reserves Clinical Leadership Develop. Workshop	--	(20,171)
Restricted reserves Seed and Grow	--	(2,241)
Restricted reserves RCC Perisurgical TC (RCC-PTC) meeting 2024	--	--
Restricted reserves Interact Europe 100	--	--
The addition to the unrestricted reserves	(133,149)	249,032
Result for the year	(383,405)	(196,930)

Stichting International Kidney Cancer Coalition

1.3. Cash flow statement 2025

The cash flow statement has been prepared according to the indirect method.

	<u>2025</u>	<u>2024</u>
	€	€
Cash flow from operating activities		
Result for the year	(383,405)	(196,930)
<i>Adjustments for:</i>		
Depreciation	306	--
Financial (income) and expenses	(7,414)	(64,944)
Operating result	(390,513)	(261,874)
<i>Change in working capital:</i>		
(Increase) / decrease in receivables	19,947	(64,719)
Increase / (decrease) in current liabilities	5,845	26,965
Cash generated from operations	(364,721)	(299,628)
<i>Interest received from bank accounts</i>	3,164	957
Net cash generated from operating activities	(361,557)	(298,671)
Cash from investing activities		
<i>Additions to the investment account</i>	--	--
Net cash from investing activities	--	--
Net cash flow	(361,557)	(298,671)
<i>Exchange gains and (losses) on cash and cash equivalents</i>	(25,361)	19,442
Net (decrease) in cash and cash equivalents	(386,918)	(279,229)
<i>Cash and cash equivalents at the beginning of the year</i>	450,259	729,488
Cash and cash equivalents at the end of the year	63,341	450,259

Stichting International Kidney Cancer Coalition

1.4. Notes to the financial statements

General notes

Activities

The activities of Stichting International Kidney Cancer Coalition, having its registered office at Ouder-Amstel primarily consist of:

- The International Kidney Cancer Coalition (IKCC) is an independent international network of patient organisations that focus exclusively, or include a specific focus, on kidney cancer. It is legally incorporated as a Foundation in the Netherlands. The organisation was born from a very strong desire among various national kidney cancer patient groups to network, cooperate and share materials, knowledge and experiences. IKCC is governed by a volunteer Board of Directors with members from a minimum of four countries.

Registered office, legal form and registration number at the chamber of commerce

Stichting International Kidney Cancer Coalition has been registered at the Chamber of Commerce under file number 62070665.

Estimates

In applying the principles and policies for drawing up the financial statements, the management of the IKCC makes different estimates and judgments that may be essential to the amounts disclosed in the financial statements. If it is necessary in order to provide the transparency required under art. 362, sub-1, book 2 of the Dutch Civil Code the nature of these estimates and judgments, including related assumptions, is disclosed in the Notes to the relevant financial statement item.

Accounting policies for the cash flow statement

The cash flow statement is prepared according to the indirect method. The cash items disclosed in the cash flow statement comprise cash at bank and in hand. Cash flows denominated in foreign currencies have been translated at average estimated exchange rates. Exchange differences affecting cash items are shown separately in the cash flow statement. Interest paid and received, dividends received and income taxes are included in cash from operating activities. Dividends paid are recognised as cash used in financing activities. The purchase consideration paid for the acquired group company has been recognised as cash used in investing activities where it was settled in cash. Any cash at bank and in hand in the acquired group company have been deducted from the purchase consideration. Transactions not resulting in inflow or outflow of cash, including finance leases, are not recognised in the cash flow statement. The value of the related asset and lease liability are disclosed in the notes to the balance sheet items. Payments of finance lease instalments qualify as repayments of borrowings under cash used in financing activities and as interest paid under cash generated from operating activities.

General accounting policies

General

The financial statements are drawn up in accordance with the Richtlijnen voor de Jaarverslaggeving C1 Kleine Organisaties-zonder-winststreven (RJK C1). The valuation of assets and liabilities and the determination of the result are based on historical costs. Unless stated otherwise in the respective basis for the specific balance sheet item, the assets and liabilities are valued according to the cost-price model. Income and expenditure are allocated to the year to which they are related. Results are only included to the extent they have been achieved on the balance sheet date. Liabilities and potential losses originating before the end of the reporting year are taken into account if they are known before the preparation of the annual accounts.

Comparison with previous year

The valuation principles and method of determining the result are the same as those used in the previous year, with the exception of the changes in accounting policies as set out in the relevant sections.

Stichting International Kidney Cancer Coalition

Foreign currency

Functional currency

Items included in the financial statements of the Foundation are valued with due regard for the currency in the economic environment in which the Foundation carries out most of its activities (the functional currency). The financial statements are denominated in euros; this is both the functional currency and presentation currency of the Foundation.

Transactions, receivables and liabilities

Transactions in foreign currencies are stated in the financial statements at the exchange rate of the functional currency on the transaction date. Monetary assets and liabilities in foreign currencies are converted to the closing rate of the functional currency on the balance sheet date. The translation differences resulting from settlement and conversion are credited or charged to the income statement, unless hedge-accounting is applied. Non-monetary assets valued at historical cost in a foreign currency are converted at the exchange rate on the transaction date.

ACCOUNTING POLICIES APPLIED TO THE VALUATION OF ASSETS AND LIABILITIES

Tangible fixed assets

Tangible fixed assets in use by the Foundation are carried at the cost of acquisition net of accumulated depreciation and, where applicable, accumulated impairment losses.

Tangible fixed assets are depreciated on a straight-line basis over their estimated useful economic lives which is estimated at 3 years.

Accounts receivable

The receivables are initially recognised at the fair value and subsequently valued at amortised costs. The fair value and amortised cost are equal to the nominal value. Provisions deemed necessary for the risk of bad debts are deducted. The provisions are determined based on individual assessment of the receivables.

Securities

Listed securities that are held for trading are carried at current value (fair value). The fair value of listed securities is the same as the market price. Listed bonds that are not held for trading are measured at amortised cost. Securities other than listed securities are valued at historical cost or lower fair value. In the latter situation, the fair value is estimated in accordance with generally accepted valuation models and techniques. Fair value gains of securities measured at fair value are directly recognised in the profit and loss account. Fair value losses of securities measured at fair value are also directly recognised in the profit and loss account. Transaction costs directly attributable to the acquisition of securities are directly recognised in the profit and loss account.

Cash at bank and in hand

Cash at bank and in hand represent cash in hand, bank balances and deposits with terms of less than twelve months. Overdrafts at banks are recognised as part of debts to lending institutions under current liabilities. Cash at bank and in hand is carried at nominal value.

Current liabilities

On initial recognition current liabilities are recognised at fair value. After initial recognition current liabilities are recognised at the amortised cost price, being the amount received, taking into account premiums or discounts, less transaction costs. This usually is the nominal value.

Reserves

Unrestricted reserves

The Foundation has unrestricted reserves, which may be freely spent within the statutory objectives of the organisation. Amendments on the unrestricted reserves are done through the results allocation of the statement of income and expenditure.

Restricted Reserves

The Foundation has Restricted reserves, which have a more limited designation than the Unrestricted Reserves. The limitation of the reserves is imposed by the Board of Directors. Amendments on the Restricted reserves are done through the result allocation of the statement of income and expenditure.

Stichting International Kidney Cancer Coalition

PRINCIPLES FOR THE DETERMINATION OF THE RESULT

General

The surplus or deficit is determined as the difference between the total income and total expenses of the year to which they relate.

Income

The income of the Foundation is recorded and recognized in the period in which the income has been effectuated. The effectuation is determined based on the sponsorship period or the realization of events.

Expense

The expenses of the Foundation are determined on a historical basis and are attributed to the reporting year to which they relate.

Interest income and interest expenses

Interest income and expenses are recognised on a pro rata basis, taking account of the effective interest rate of the assets and liabilities to which they relate. In accounting for interest expenses, the recognised transaction expenses for loans received are taken into consideration.

Dividends

Dividends to be received from participations and securities not carried at net asset value are recognised as soon as the Foundation has acquired the right to them.

Stichting International Kidney Cancer Coalition

1.5. Notes to the balance sheet

ASSETS

FIXED ASSETS

Description	Hardware & software	Total
Balance as at 31 December 2024		
Cost	--	--
Accumulated depreciation	--	--
Net book value	--	--
Movements in 2025 – cost		
Additions	1,000	1,000
	1,000	1,000
Movements in 2025 – accumulated depreciation		
Depreciation charge	(306)	(306)
	(306)	(306)
Balance as at 31 December 2025		
Cost	1,000	1,000
Accumulated depreciation	(306)	(306)
Net book value	694	694

CURRENT ASSETS

Receivables

	31-Dec-25	31-Dec-24
	€	€
Other prepayments and accrued income		
Prepaid expenses	45,821	65,159
Accrued bank interest income	1,957	--
Amounts receivable	--	2,566
	<u>47,778</u>	<u>67,725</u>
Securities		
ING Investment account	<u>710,978</u>	<u>682,367</u>
Cash at bank and in hand		
ING EUR reserve operating account	44,808	201,956
ING EUR payment account	17,595	20,043
ING US Dollar account	938	228,260
	<u>63,341</u>	<u>450,259</u>

Stichting International Kidney Cancer Coalition

1.5. Notes to the balance sheet

LIABILITIES

Foundation's capital

	<u>31-Dec-25</u>	<u>31-Dec-24</u>
	€	€
Restricted reserves Global Kidney Cancer Summit		
Value as of 1 January	140,000	140,000
Utilization	(134,111)	(142,375)
From/ to unrestricted reserves	--	142,375
Value as of 31 December	<u>5,889</u>	<u>140,000</u>
	<u>31-Dec-25</u>	<u>31-Dec-24</u>
	€	€
Restricted reserves World Kidney Cancer Day		
Value as of 1 January	120,000	150,000
Utilization	(53,105)	(126,689)
From/ to unrestricted reserves	--	96,689
Value as of 31 December	<u>66,895</u>	<u>120,000</u>
	<u>31-Dec-25</u>	<u>31-Dec-24</u>
	€	€
Restricted reserves DISCERN		
Value as of 1 January	59,254	--
Utilization	(28,646)	(1,246)
From/ to unrestricted reserves	--	60,500
Value as of 31 December	<u>30,608</u>	<u>59,254</u>
	<u>31-Dec-25</u>	<u>31-Dec-24</u>
	€	€
Restricted reserves Shared Decision Making		
Value as of 1 January	60,781	45,000
Utilization	(25,562)	(40,117)
From/ to unrestricted reserves	9,781	55,898
Value as of 31 December	<u>45,000</u>	<u>60,781</u>
	<u>31-Dec-25</u>	<u>31-Dec-24</u>
	€	€
Restricted reserves CARE1		
Value as of 1 January	10,676	--
Utilization	(7,375)	(3,824)
From/ to unrestricted reserves	(3,301)	14,500
Value as of 31 December	<u>--</u>	<u>10,676</u>

Stichting International Kidney Cancer Coalition

1.5 Notes to the balance sheet

	<u>31-Dec-25</u>	<u>31-Dec-24</u>
	€	€
Restricted reserves Dashboard Project		
Value as of 1 January	2,000	--
Utilization	(1,457)	(1,694)
From/ to unrestricted reserves	--	3,694
Value as of 31 December	<u>543</u>	<u>2,000</u>

	<u>31-Dec-25</u>	<u>31-Dec-24</u>
	€	€
Restricted reserves Global Patient Survey		
Value as of 1 January	--	90,000
Utilization	--	(107,605)
From/ to unrestricted reserves	--	17,605
Value as of 31 December	<u>--</u>	<u>--</u>

	<u>31-Dec-25</u>	<u>31-Dec-24</u>
	€	€
Restricted reserves Clinical Leadership Develop. Workshop		
Value as of 1 January	--	50,000
Utilization	--	(20,171)
From/ to unrestricted reserves	--	(29,829)
Value as of 31 December	<u>--</u>	<u>--</u>

	<u>31-Dec-25</u>	<u>31-Dec-24</u>
	€	€
Restricted reserves Seed and Grow		
Value as of 1 January	--	--
Utilization	--	(2,241)
From/ to unrestricted reserves	--	2,241
Value as of 31 December	<u>--</u>	<u>--</u>

	<u>31-Dec-25</u>	<u>31-Dec-24</u>
	€	€
Restricted reserves RCC Perisurgical TC (RCC-PTC) meeting 2024		
Value as of 1 January	60,000	--
Utilization	--	--
From/ to unrestricted reserves	(60,000)	60,000
Value as of 31 December	<u>--</u>	<u>60,000</u>

	<u>31-Dec-25</u>	<u>31-Dec-24</u>
	€	€
Restricted reserves Interact Europe 100		
Value as of 1 January	1,000	--
Utilization	--	--
From/ to unrestricted reserves	(1,000)	1,000
Value as of 31 December	<u>--</u>	<u>1,000</u>

Stichting International Kidney Cancer Coalition

1.5 Notes to the balance sheet

	<u>31-Dec-25</u>	<u>31-Dec-24</u>
	€	€
Unrestricted reserves		
Value as of 1 January	658,526	774,167
To restricted reserves	54,520	(364,673)
Operating result	(133,149)	249,032
Value as of 31 December	<u><u>579,897</u></u>	<u><u>658,526</u></u>

CURRENT LIABILITIES

	<u>31-Dec-25</u>	<u>31-Dec-24</u>
	€	€
Accounts payable		
Creditors	<u><u>47,100</u></u>	<u><u>60,321</u></u>

	<u>31-Dec-25</u>	<u>31-Dec-24</u>
	€	€
Accruals and other payables		
Accrued expenses	46,859	27,142
Credit cards	--	651
	<u><u>46,859</u></u>	<u><u>27,793</u></u>

Stichting International Kidney Cancer Coalition

1.6. Notes to the statement of income and expenditure

	<u>2025</u>	<u>2024</u>
	€	€
Net turnover		
Sustaining partnerships	172,456	357,615
Projects	209,341	262,560
	<u>381,797</u>	<u>620,175</u>

The net turnover of 2025 decreased by -38% versus prior year.

	<u>2025</u>	<u>2024</u>
	€	€
Expenditure		
Objective 1: To strengthen the capacity of current and emerging affiliates in their support for patients with kidney cancer.	232,338	234,333
Objective 2: To advocate for access to best care.	118,047	126,906
Objective 3: To increase awareness of kidney cancer globally.	172,860	192,213
Objective 4: To be a global authority in the provision of credible and up-to-date kidney cancer information.	99,896	120,914
Objective 5: To foster projects promoting the voice of kidney cancer patients in research activities worldwide.	149,475	207,683
	<u>772,616</u>	<u>882,049</u>

	<u>2025</u>	<u>2024</u>
	€	€
Financial income		
Investment account result	27,612	44,545
ING bank interest income	5,163	957
Foreign currency exchange gains	--	19,442
	<u>32,775</u>	<u>64,944</u>

Financial expenses		
Foreign currency exchange losses	25,361	--
	<u>25,361</u>	<u>--</u>
	<u>7,414</u>	<u>64,944</u>